Monitor Decipher Prostate volume trends and the impact of Convergent Genomics acquisition on bladder cancer testing revenue. The narrowed guidance and flat non-GAAP EPS YoY suggest limited near-term upside catalysts despite the buyback authorization.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $24.00entry
- T+1 · 11d ago +0.67%α +0.35% · $24.16
- T+5 · 5d ago +2.63%α −0.67% · $24.63
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Veracyte reported Q3 2026 revenue of $151.8M (+15% YoY), slightly above the $147.2M consensus, and GAAP EPS of $0.38, below the $0.41 Street estimate. The company narrowed its full-year revenue guidance to $590M-$593M from $590M-$596M, reflecting a modest trim to the top end. A $100M share repurchase program was announced. Decipher Prostate volume was below expectations, while Afirma outperformed.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $151.8M, +15% YoY vs $131.9M; consensus was $147.2M
- GAAP diluted EPS $0.38 vs $0.24 YoY; consensus was $0.41
- Non-GAAP diluted EPS $0.51, flat YoY
- Testing revenue $146.4M, +15% YoY; Decipher Prostate +12% to $92.3M, Afirma +19% to $51.5M
- Full-year 2026 revenue guidance narrowed to $590M-$593M from $590M-$596M; testing revenue guidance trimmed to $571M-$573M from $576M-$582M
- Adjusted EBITDA margin guidance unchanged at >26%
- Board authorized $100M share repurchase program, expiring in 12 months
- Acquired Convergent Genomics, Inc. to expand urology portfolio
- Secured Medicare reimbursement for Prosigna Breast ROR test in the U.S.
- Cash, cash equivalents and short-term investments $370.5M as of Sep 30, 2026
Financial Impact
Revenue beat consensus by ~3.1%; GAAP EPS missed by ~7.3%; guidance narrowed slightly; $100M buyback authorized (2.6% of $3.9B market cap)
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Testing revenue | $146.4M | +14.6% |
| Product revenue | $4.6M | +40.1% |
| Biopharmaceutical and other revenue | $709.0K | -13.0% |
Risk Factors
- Decipher Prostate volume below expectations may signal competitive or reimbursement headwinds
- Full-year revenue guidance trimmed at the top end, indicating slower H2 momentum
- Non-GAAP EPS flat YoY despite revenue growth, suggesting margin pressure from higher operating expenses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001384101-26-000053 |
| Document: vcyt-20261104.htm | 0001384101-26-000053 |
| Document: 0001384101-26-000053-index-headers.html | 0001384101-26-000053 |
| Document: 0001384101-26-000053-index.html | 0001384101-26-000053 |
| Document: 0001384101-26-000053.txt | 0001384101-26-000053 |
| 8-K Data (Synthetic) | 0001384101-26-000053 |
Track record
22 reports on VCYT
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +20.37% at T+20 after the Jun 11, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $24.63 Now $24.01 −2.52% settles Dec 11
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $24.00 Now $24.01 +0.04% settles Dec 4
- Nov 4, 202612d ago 8-K Neutral 5/10 Viewing Entry $24.00 Now $24.01 +0.04% settles Dec 4
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $50.01 Now $24.01 −51.99% settles Nov 30
- Oct 28, 202619d ago Insider Cluster Neutral 2/10 Entry $52.17 Now $24.01 −53.98% settles Nov 27
- Oct 28, 202619d ago Insider Cluster Neutral 3/10 Entry $52.17 Now $24.01 −53.98% settles Nov 27
- Oct 27, 202620d ago 144 Neutral 2/10 Entry $50.31 Now $24.01 −52.28% settles Nov 25
- Oct 27, 202620d ago 144 Neutral 2/10 Entry $50.31 Now $24.01 −52.28% settles Nov 25
- Sep 22, 20267w ago Insider Cluster Neutral 2/10 Entry $43.82 to $46.22 Now $24.01 −45.21% ▲ +5.48% +4.79% vs SPY
- Sep 14, 20269w ago Press Release Bullish 6/10 Entry $40.14 to $43.11 Now $24.01 −40.18% ▲ +7.40% +4.68% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers